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Background: Ginsenoside Rg1 (Rg1) is one of the most active ingredients in Panax ginseng and has been proven
to have anti-oxidative and anti-aging properties. However, there have been few reports concerning the anti-aging
effects of Rg1 on the hematopoietic microenvironment and bone marrow stromal cells (BMSCs).
Methods: Thirty Sprague-Dawley rats were randomly divided into four groups (control, D-galactose (D-gal)-administration,
Rg1-treatment, and D-gal-administration + Rg1-treatment groups). After D-gal and Rg1 treatment, BMSCs were extracted
from femoral bone marrow for culture. After three passages, BMSCs were tested by senescence-associated β-galactosidase
(SA-β-gal) staining, flow cytometric cell cycle phase distribution assay, CCK-8 cell proliferation assay, oxidative
stress (reactive oxygen species [ROS], superoxide dismutase [SOD], and malondialdehyde [MDA]) assays, inflammatory
marker (interleukin (IL)-2, IL-6, and tumor necrosis factor (TNF)-α) enzyme-linked immunosorbent assay (ELISA), stem cell
factor (SCF) ELISA, and senescence-associated protein (p16, p21, and p53) Western blotting.
Results: Compared to the D-gal-administration group, the D-gal-administration + Rg1-treatment group showed significantly
decreased levels of SA-β-gal + cell %, ROS, MDA, inflammatory marker expression, and senescence-associated
protein expression as well as significantly increased levels of S-phase %, cell proliferation, SOD activity, and SCF
expression. Compared to controls, the Rg-1-treatment group displayed significantly reduced levels of SA-β-gal +
cell %, G1 phase %, ROS, MDA, inflammatory marker expression, senescence-associated protein expression, and
SCF expression as well as significantly increased levels of S-phase %, cell proliferation, and SOD activity.
Conclusions: Rg1 improves the anti-aging ability of hematopoietic microenvironment through enhancing the
anti-oxidant and anti-inflammatory capacities of BMSCs.
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GinsengBackground
With the growing population and extended lifespan,
aging has become a worldwide problem due to its sub-
stantial associated disability. For example, aging of the
hematopoietic system and bone marrow probably leads
to hematologic disease [1-3]. Bone marrow is the most
important hematopoietic organ and is composed of
hematopoietic cells and bone marrow stromal cells
(BMSCs) at different stages of development. BMSCs, as* Correspondence: yaping_wang023@163.com
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onment, are where hematopoietic stem cells (HSCs)
lodge, proliferate and differentiate. It is within the
hematopoietic microenvironment that HSCs generate
specific progenitor cells and the self-renewal divisions
necessary to sustain themselves. The hematopoietic
microenvironment may be sensitive to systemic senes-
cence caused by natural aging or chemical induction.
Thus, the senescence that occurs in the hematopoietic
microenvironment and BMSCs may cause degenerative
dysregulation of HSCs.
Traditional Chinese Medicine (TCM) theory indicates
that the debility that occurs in bone marrow durings is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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“blood”. Therefore, the principle for regulating bone
marrow senescence should be based on invigorating
both “qi” and “blood”. Ginsenoside Rg1 (Rg1) is one of
the most active ingredients in Panax ginseng and has
been proven to have various pharmacological actions in
anti-oxidation and anti-aging [4]. Moreover, Rg1 has
been extensively observed to enhance hematopoietic
effects in mice and rats with drug and radiation-
induced senescence, including the resitance to aging
process of HSCs by inhibited the expression of p16
INK4a and p21 Cip1/Waf1 both at gene and protein levels
and the promotion to hematopoietic cytokines such as
Stem Cell Factor (SCF) and Granulocyte-Macrophage
Colony-Stimulating Factor (GM-CSF) [5,6].
The D-galactose (D-gal)-induced aged rat model is
widely regarded as an ideal model to study mechanisms
and screen drugs for HSC aging. Specifically, chronic
systemic exposure of rodents to D-gal induces acceler-
ated aging, including regression of bone marrow and the
hematopoietic system that are similar to symptoms in
natural aging [7,8]. In our previous study, we demon-
strated that Rg1 possesses the capacity for anti-aging ac-
tivity in HSCs both in vitro and vivo [9]. Although the
aging of the hematopoietic microenvironment and
BMSCs, as the supporting material of the HSCs, can also
influence the hematopoietic function of bone marrow,
there have been few reports concerning the anti-aging
effects of Rg1 on the hematopoietic microenvironment
and BMSCs. Thus, to better elucidate the underlying
mechanism (s) of Rg1 in age-associated hematopoietic
microenvironment degeneration, here we investigated




Three month old male Sprague-Dawley rats were pur-
chased from the Medical and Laboratory Animal Center
of Chongqing (Chongqing, China) and housed in a
temperature and light-controlled room with free access
to water and food. All treatments were performed under
sodium pentobarbital anesthesia, and all efforts were
made to minimize animal suffering. The Committee on
Ethics of Animal Experimentation at Chongqing Medical
University (Chongqing, China) approved the protocols
of this study prior to its implementation (Approval no.:
2013031).
Twenty rats were randomly divided into four groups
(control group, D-gal-administration group, Rg1-
treatment group, and D-gal-administration + Rg1-treat-
ment group). In the D-gal-administration group, D-gal
(120 mg/kg · d) was injected subcutaneously daily into
rats for 42 days. In the D-gal-administration + Rg1-treatment group, ginsenoside Rg1 (20 mg/kg · d) was
injected peritoneally daily concomitantly for 28 days
from day 15 of D-gal injection. All control animals were
given saline in the same volume subcutaneously and
peritoneally, respectively. In the Rg1-treatment group,
saline at the same volume with D-gal injection was
injected subcutaneously for 42 days, and Rg1 (20 mg/kg · d)
was injected peritoneally for 28 days from day 15 of saline
injection.Reagents
Ginsenoside Rg1 (RSZD-121106, Purity = 98.3%) was
purchased from Xi’an Haoxuan Biological Technology
Co., Ltd (Xi’an, China), dissolved in ddH2O at the con-
centration of 20 mg/ml, and sterilized by ultrafiltra-
tion. The SOD kit and MDA kit were purchased from
Nanjing Jiancheng Bioengineering Institute (Nanjing,
China). The IL-2 kit, IL-6 kit, and goat anti-rabbit sec-
ondary antibody were purchased from Wuhan Boster
Bio-engineering Co., Ltd. (Wuhan, China). The TNF-α
Kit was obtained from Uscn Life Science Inc. (Wuhan,
China). The BCA kit and SA-β-gal Staining kit were
purchased from Beyotime Institute of Biotechnology
(Shanghai, China). The anti-β-tubulin III antibody was
obtained from Sigma Co. LLC. The anti-GFAP anti-
body was purchased from Wuhan Sanying Biotechnol-
ogy Inc. (Wuhan, China).
Sample collection
The bone marrow cells were collected according to
Raghavendran’s method [5]. The femoral bones were
separated out of the body, briefly soaked in 75% alcohol,
and flushed three times in phosphate buffer solution
(PBS) containing antibiotics (Penicillin–Streptomycin)
under sterile conditions. The epiphyses of each bone
were cut off. Bone marrow cell suspensions were pre-
pared by flushing the diaphysis with PBS through syringe
needles for three to five times. Then, full bone marrow
cells were implanted in 25-cm2 tissue flasks containing
5 ml DMEM supplemented with 10% FBS and 1%
penicillin-streptomycin. The cells were incubated in a
37°C, 5% CO2-humidified chamber. After 72 h of incu-
bation, the supernatant and unattached cells were re-
moved. The adherent cells were fed with fresh medium
and incubated for an additional two days. The medium
was pipetted off and discarded, the cells were trypsin-
digested and detached, and then passaged to a new flask.
The cultures were fed every three days by replacement
of the medium. After three passages, BMSCs achieved
80% confluence. The confluent cell layers were washed
twice with PBS. Adherent BMSCs were detached with
0.25% trypsin with EDTA and collected for further
assays.
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cytochemical staining
SA-β-gal is one of the most widely used biomarkers for
aging cells [7,8]. The BMSCs were collected at passage
three, and the SA-β-gal staining was performed according
to the manufacturer’s instructions. Briefly, 5 × 104 purified
BMSCs from each animal were inoculated onto a six-well
plate (with one slide per each well) and incubated for
three days. Slides were washed twice with PBS, fixed in
Fixative Solution for 10 min at room temperature, and
stained with Staining Solution for 12 h at 37°C without
CO2. Approximately 1 × 10
4 cells were separated on each
slide, and 400 cells were analyzed for each animal. The
percentage of SA-β-gal-positive cells was calculated by
counting the number of blue cells under bright field illu-
mination and then calculating the ratio of SA-β-gal stain-
ing positive cells (%) in each group.
Cell cycle phase distribution assay by flow cytometry
BMSCs were collected at a concentration of 5 × 105
cells/ml and fixed with 70% cold ethanol at 4°C over-
night. After centrifugation at 1000 rpm for 5 min, cells
were incubated with propidium iodide (PI) at 4°C for
30 min in the dark and were subjected to flow cytometry
using a FAC Scan Flow cytometer (BectonDickinson,
New Jersey, USA) to determine the percentage of cells in
each cell cycle phase.
CCK-8 cell proliferation assay
For the quantitative determination of cellular prolifera-
tion and viability, we performed the CCK-8 assay. This
assay was performed after BMSCs were collected at pas-
sage three. The cells were washed, counted, and seeded
at a density of 4 × 105 cells/ml per well in 96-well plates.
At 24, 48, 72, 96, and 120 h after BMSC seeding, CCK-8
solution was added 4 h prior to the end of incubation.
Cell viability was measured with a spectrophotometer at
an absorbance of 450 nm.
Inflammatory cytokine and Stem Cell Factor (SCF)
detection in BMSCs by ELISA
The supernatant of the cell culture on passage three was
collected, and levels of three inflammatory cytokines
(IL-2, IL-6, and TNF-α) as well as SCF in each group
were measured by ELISA according to the kit manufac-
turer’s instructions.
Detection of oxidation-associated biomarkers
At passage three, BMSCs were collected and lysed in an
ice bath for 30 min. After centrifugation (12000 rpm, 4°C,
30 min), the supernatant was collected. SOD activity – de-
termined using the commercially-available WST-1 assay
kit – and MDA content were detected by chemical colori-
metric analysis according to the kit manufacturer’sinstructions. The SOD activity assay is based on its ability
to inhibit the oxidation of hydroxylamine by O2- produced
by the xanthine-xanthineoxiase system. The results of the
SOD activity assay were expressed as ratios of SOD
suppression.
The thiobarbituric acid reaction (TBAR) method was
used to determine the MDA, which can be measured at
a wavelength of 532 nm by reacting TBA to form a
stable chromophore. MDA content was expressed as
nmol per milligram of BMSC protein. ROS production in
BMSCs was measured using a DCFH-DA fluorescence
flow cytometric assay. At passage three, the fluorogenic
substrate solution was added to the medium and incu-
bated at 37°C and 5% CO2 for 45 min. After being washed
with cold PBS, the cells were quickly analyzed by FACS
Calibur (BectonDickinson, USA).Western blotting analysis
BMSCs in each group were collected at passage three.
Total protein was extracted, and the concentrations
were measured by a BCA procedure. Samples containing
50 μg protein were separated on SDS-PAGE and trans-
ferred to PVDF membranes. Membranes were incubated
overnight at 4°C with anti-p16, anti-21, and anti-53 anti-
bodies (all diluted 1:500). The secondary antibody was
diluted 1:5000 in TBST. The membranes were visualized
using the enhanced chemiluminescence (ECL) detection
system (Pierce, USA). β-actin was used as an internal
control. Integral optical density (IOD) was quantified
using Image Pro Plus (Media Cybernetics).
Statistical analysis
SPSS v17.0 was used for all statistical analyses. One-way
ANOVA was used for comparing mean values across
groups, and multiple comparisons were made using the
LSD test. Differences were considered significant at P <
0.05.
Results
Rg1 reduces SA-β-Gal staining of BMSCs in aged rats
The intensity of SA-β-gal staining was evaluated by
means of the percentage of SA-β-gal positive cells (%)
(Figure 1). The percentages of SA-β-gal positive cells
were not significantly different between the control
group and the Rg1-treatment group (Figure 1). As ex-
pected, the D-gal-administration group induced a signifi-
cant increase in the percentage of SA-β-gal positive cells
compared to that of the control group (p < 0.05; Figure 1).
However, in the D-gal-administration + Rg1-treatment
group, the percentage of SA-β-gal positive cells was sig-
nificantly reduced (p < 0.05; Figure 1). These findings sug-
gest that Rg1 can protect BMSCs against senescence.
Figure 1 Rg1’s Effect upon Senescence-Associated β-Galactosidase
Staining. The BMSCs were collected on day 5 of passage 3. The
control and Rg1-treatment group showed normal structures, while
D-gal-administration group showed that aged cells are stained in
blue in the cytoplasm. Rg1 treated group exhibited a small number
of blue stained cells. All the figures of BMSCs were shown with the
light microscope at 200 times magnification. (A) The control group,
(B) D-gal-administration group, (C) Rg1-treatment group, and (D)
D-gal-administration + Rg1-treatment group. (E) a: comparison
with the control group (p < 0.05); b: comparison with the
D-gal-administration group (p < 0.05). Each error bar represents
the standard deviation (SD).
Figure 2 Rg1’s Effect upon the Cell Cycle Phase Distribution of BMSCs
in Aged Rats. The BMSCs were collected on day 5 of passage 3. Cell
cycle phase distribution was measured by flow cytometry with ≥5 ×
105 cells tested for each sample. a: comparison with the control group
(p < 0.05); b: comparison with the D-gal-administration group (p < 0.05).
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When compared to the D-gal-administration group,
the BMSCs in both the Rg1-treatment and D-gal-
administration + Rg1-treatment groups displayed G1-phase
shortening, which is the reverse of the effect observed in
the control group (p < 0.05; Figure 2). BMSCs from the D-
gal-administration group displayed G1-phase arrest, and
the percentages of cells in S phase were significantly de-
creased compared to that of the control group (p < 0.05;
Figure 2). However, the percentages of cells in S phase in
both the Rg1-treatment and D-gal-administration + Rg1-treatment groups were significantly elevated (p < 0.05;
Figure 2). There were no significant differences among
the four groups regarding cell percentages in M phase
(Figure 2).
Rg1 Promotes BMSC proliferation
As expected, D-gal administration led to significant in-
hibition of BMSC proliferation compared to controls
(p < 0.05; Figure 3). However, after Rg1 treatment,
BMSC proliferation in the D-gal-administration + Rg1-
treatment group was elevated significantly compared to
the D-gal-administration group (p < 0.05; Figure 3).
Rg1 affects inflammatory cytokine and SCF levels of
BMSCs in aged rats
The levels of IL-2, IL-6 and TNF-α significantly in-
creased, and SCF significantly decreased, in the BMSCs
from the D-gal-administration group when compared
with the control group (p < 0.05; Figure 4). However, the
levels of the three inflammatory cytokines were signifi-
cantly reduced in the D-gal-administration + Rg1-treat-
ment group relative to the D-gal-administration group
(p < 0.05; Figure 4). Conversely, the level of SCF was sig-
nificantly elevated in the D-gal-administration + Rg1-
treatment group compared to the D-gal-administration
group. Simultaneously, Rg1 treatment did not signifi-
cantly reduce the levels of IL-2, IL-6 and TNF-α in the
Rg1-treatment group compared with controls, but the
level of SCF was significantly promoted in the Rg1-
treatment group compared with controls (p < 0.05;
Figure 4). These findings indicate that inflammation in
D-gal-induced aged BMSCs is alleviated, while SCF
expression is promoted, by Rg1 treatment.
Rg1’s anti-oxidative effects upon BMSCs in aged rats
The oxidative stress produced by reactive oxygen species
(ROS) is one of the main causes of cell senescence.
Superoxide dismutase (SOD) participates in the removal of
ROS from the cellular environment, and malondialdehyde
Figure 3 Rg1’s Effect upon Cell Proliferation of BMSCs in Aged Rats. The BMSCs were collected on day 5 of passage 3. (A, B) There were no differences
among the four groups at days one and two by analysis of variance (ANOVA). However, at days three, four, and five, there were significant differences
between the four groups by ANOVA. a: comparison with the control group (p < 0.05); b: comparison with the D-gal-administration group (p < 0.05). Each
error bar represents the standard deviation (SD).
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that is widely used as a marker of oxidative stress. We eval-
uated cellular ROS levels, SOD activity, and MDA content
in the BMSCs to determine whether the anti-aging effects
of Rg1 are mediated by alleviating oxidative stress. In the
DCFH-DA assay, the cellular ROS levels were elevated sig-
nificantly in the D-gal-administration group when com-
pared with controls with significant inhibitory effects of
Rg1 observed in the D-gal-administration + Rg1-treatment
group (p < 0.05; Figure 5). In the Rg1-treatment group, the
level of ROS production was not inhibited significantly
compared to controls (Figure 5). When compared to the
control group, the ratio of SOD suppression decreased
significantly and the MDA content increased significantly
in BMSCs in the D-gal-administration group (p < 0.05;
Figure 5). Meanwhile, Rg1 significantly rescued the reduc-
tion in SOD activity, and partially rescued the increase in
MDA content, in the D-gal-administration + Rg1-treat-
ment group (p < 0.05; Figure 5). Interestingly, the Rg1-
treatment group also significantly increased SOD activity
and significantly reduced MDA content (p < 0.05; Figure 5),Figure 4 Rg1’s Effect upon Inflammatory Cytokine Secretion by BMSCs in A
Interleukin (IL)-6, (B) IL-2, and (C) tumor necrosis factor (TNF)-α. a: com
the D-gal-administration group (p < 0.05). Each error bar represents thshowing Rg1 exerts anti-oxidant effects by enhancing the
activity of endogenous anti-oxidative defense enzymes.
Rg1 affects p16, p21, and p53 expression in BMSCs of
aged rats
The p16INK4a-retinoblastoma (Rb) pathway and the
p19Arf-Mdm2-p53-p21Cip1/Waf1 pathway are two important
signal transduction pathways involved in cell aging and
cell cycle arrest. According to Western blotting analysis,
the levels of p16INK4a, p21Cip1/Waf1, and p53 were signifi-
cantly higher in the D-gal-administration group than in
the control group (p < 0.05; Figure 6). With Rg1 treat-
ment, the levels of these three proteins declined signifi-
cantly (p < 0.05; Figure 6).
Discussion
During natural aging, the hematopoietic system under-
goes progressive morphologic and functional changes
that occur in both the hematopoietic stem/progenitor
cells and the hematopoietic niche, such as declines in
hematopoietic capacity and tumorigenesis monitoring.ged Rats. The BMSCs were collected on day 5 of passage 3. (A)
parison with the control group (p < 0.05); b: comparison with
e standard deviation (SD).
Figure 5 Rg1’s Effect upon Oxidative Stress and Anti-Oxidant Activity of BMSCs in Aged Rats. The BMSCs were collected on day 5 of passage 3.
(A) Reactive oxygen species (ROS) levels, (B) superoxide dismutase (SOD) activity, and (C) malondialdehyde (MDA) content. a: comparison with
the control group (p < 0.05); b: comparison with the D-gal-administration group (p < 0.05). Each error bar represents the standard deviation (SD).
Figure 6 Rg1’s Effect on Senescence-Associated Protein Expression of BMSCs in Aged Rats. The BMSCs were collected on day 5 of passage 3. (A)
Western blots showing β-actin, p16, p21, and p53 protein expression. (B) The integral optical density (IOD) values for p16, p21, and p53 proteins
normalized to β-actin were calculated. a: comparison with the control group (p < 0.05); b: comparison with the D-gal-administration group (p < 0.05).
Each error bar represents the standard deviation (SD).
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counteract hematopoietic degeneration in order to pre-
vent certain blood diseases associated with aging. Our
previous study demonstrated that Rg1 administration in
mice enhances the resistance of HSC/HPCs to ionizing
radiation-induced senescence by inhibiting oxidative
stress reactions. However, the effects of Rg1 upon
hematopoietic microenvironment aging remained un-
known. Thus, to better elucidate the underlying mech-
anism (s) of Rg1 in age-associated hematopoietic
microenvironment degeneration, here we investigated
the effects of Rg1 on the BMSCs of a D-gal-induced
aged rat model.
The cell cycle phase distribution of BMSCs reflects the
proliferative activity of BMSCs and is an important indi-
cator of hematopoietic-sustaining function. The over-
whelming majority of cells within the bone marrow in a
natural or drug-induced aging scenario remain in the G1
phase and cannot pass the G1/S check point [6], result-
ing in a decrease in the proliferation index. Accordingly,
the decrease of BMSCs in aged rats could be due to an
inhibition of a cell proliferation and/or an increase in
cell apoptosis. To obtain a deeper insight into the mech-
anism (s) underlying the anti-aging activity of Rg1 in a
D-gal induced aged rat model, we performed cell cycle
phase distribution and apoptosis analysis of BMSCs
through flow cytometry. As a result, we found significant
decreases in BMSCs in the aged rat resulting from an in-
hibition of the cell proliferation as well as an increase in
cell death following D-gal administration, which is in
agreement with previous in vitro research on HSCs [5,7].
Moreover, we found that Rg1 facilitated BMSC prolifera-
tion, prevented BMSCs from proceeding to apoptosis, and
also promoted the recovery of BMSCs. However, the de-
tailed molecular mechanism (s) underlying Rg1’s effects
upon cell cycle-related and apoptosis-related cellular path-
ways in the BMSC remains to be elucidated.
SCF is an acid glycoprotein secreted from stromal cells
into the hematopoietic microenvironment and plays an
important role in the hematopoiesis during embryonic
development. All sites where hematopoiesis occurs, such
as the bone marrow, express SCF. Mice die from severe
anemia under conditions lacking SCF or SCF receptors
[10]. SCF provides signalling cues that direct HSCs to
their hematopoietic microenvironment and also plays an
important role in HSC maintenance [10,11]. The present
study indicates that Rg1 is able to elevate BMSC-
secreted SCF in D-gal-induced aged rats, suggesting that
Rg1 promotes hematopoietic function in aged rats by
contributing to the maintenance of HSCs.
The foregoing results display that the positive effects
resulting from the Rg1 treatment include promotion of
cell proliferation, migration, and anti-apoptotic activity.
We also evaluated anti-senescence in the D-gal-inducedaged rat model by the aging biomarker SA-β-gal, which
reflects the function of the lysosomes and accumulates
in aging cells as lysosomes begin to malfunction. We
found that Rg1 administration significantly decreased
SA-β-gal expression in the bone marrow of aged rats, in-
dicating that Rg1 is able to protect against BMSC senes-
cence, which coincides with our previous in vitro study
on Rg1’s effect on HSC senescence [6].
Aging has been associated with chronic inflammation
[12-14]. When chronic inflammation occurs in aged
bone marrow, a variety of BMSC products and inflam-
matory cytokines, such as IL-2, IL-6, and TNF-α, are re-
leased [15-17]. In the present study, Rg1 treatment
significantly reduced the levels of IL-2, IL-6, and TNF- α
in aged rats, suggesting that Rg1 can protect BMSCs
from age-associated chronic inflammation.
Oxidative damage caused by ROS is one of key sources
of cellular senescence [18-20]. ROS are formed as a nat-
ural by-product of the normal metabolism of oxygen
and have important roles in cell signaling and homeosta-
sis [21]. Additionally, ROS constitute one of the stimuli
that induce cellular senescence [22]. Senescence occurs
when there is an imbalance between increased ROS
levels and decreased anti-oxidant defenses. When ROS
production increases and/or ROS elimination downregu-
lates, there will be an increase in ROS that results in lipidic
oxidative damage to cellular function and structure [23].
MDA content reflects this lipidic oxidative damage in vivo,
and SOD activity reflects antioxidant defense. In the
present study, Rg1 promoted SOD activity while decreasing
ROS and MDA content in both aged and control rats, sug-
gesting that Rg1 induces anti-oxidant defense in the
hematopoietic microenvironment of aged rats.
A variety of intracellular and extracellular stresses can
promote cellular senescence [24]. These stressors – in-
cluding oxidative stress, oncogene activation, and radi-
ation stress – engage various intracellular signaling
pathways such as the p16INK4a-retinoblastoma (Rb) path-
way and the p19Arf-Mdm2-p53-p21Cip1/Waf1 pathway. Ac-
cording to this study, ROS and MDA levels, as well as
the senescence-related proteins (p16, p21, and p53) in
aged rats were significantly higher compared to controls.
Based on these combined findings, we speculate that the
underlying mechanism of BMSC aging in the D-gal rat
model is oxidative stress. Interestingly, Rg1 inhibited ex-
pression of these senescence-related proteins not only in
aged rats but also in controls. Furthermore, activated
p53 activates p21, which induces cell-cycle arrest by
inhibiting cyclin E-Cdk2. Additionally, p16INK4a inhibits
cell-cycle progression by targeting cyclin D–Cdk4 and
cyclin D–Cdk6 complexes. Both p21 and p16INK4a pre-
venting the phosphorylation of pRb, thus resulting in
continued repression of E2F target genes required for
S-phase onset. Thus, these senescence-related protein
Hu et al. BMC Complementary and Alternative Medicine  (2015) 15:119 Page 8 of 8findings correspond to the findings from our cell cycle
and cell proliferation assays.Conclusion
Rg1 improves the anti-aging ability of hematopoietic
microenvironment through enhancing the anti-oxidant
and anti-inflammatory capacities of BMSCs. Further
research is needed to investigate the detailed molecular
mechanism (s) underlying Rg1’s effects upon cell cycle-
related and apoptosis-related cellular pathways in BMSCs.
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